The healthcare industry is witnessing a transformative shift with the integration of genomic medicine into standard clinical practice. At the forefront of this revolution is GeneDx, a leader in rare disease diagnosis, and its CEO, Katherine Stueland. Stueland’s recent recognition as a 2026 Fierce 50 honoree for Health Equity underscores the significant impact GeneDx is having on patient care and the broader healthcare landscape.
GeneDx’s mission is to empower individuals to live healthier lives through the power of genomics. By combining deep clinical expertise, advanced technology, and the world’s largest rare disease genomic dataset, GeneDx Infinity™, the company is making earlier and more accurate diagnoses a standard part of healthcare. This approach enables a more proactive, precise, and efficient healthcare system, ultimately improving patient outcomes.
GeneDx’s Innovative Approach to Genomic Medicine
Under Stueland’s leadership, GeneDx has made significant strides in integrating genomic testing into routine clinical care. The company’s ExomeDx™ and GenomeDx® tests, ranked #1 by expert geneticists and granted FDA Breakthrough Device designation, are at the heart of this innovation. These tests enable clinicians to deliver precise, fast, and actionable diagnoses, which are crucial for patients with rare diseases.
GeneDx Infinity™ serves as the backbone of the company’s diagnostic capabilities. This vast repository of rare disease genomic data not only supports clinical diagnostics but also fuels biopharmaceutical research. By leveraging AI-driven genomic intelligence, GeneDx is pushing the boundaries of what’s possible in precision medicine. Over the past 25 years, GeneDx has diagnosed more than 4,800 genetic diseases and contributed to over 1,000 research publications, solidifying its position as a genomics pioneer.
The Impact of Early and Accurate Diagnosis
Stueland emphasizes the importance of early diagnosis in transforming patient care. ‘When patients get the right diagnosis earlier, everything that follows can change,’ she said. Genomic medicine has the power to fundamentally improve how care is delivered, and GeneDx is proving what’s possible when genomics becomes part of the standard of care.
For patients with rare diseases, obtaining a diagnosis can be a lengthy and complex process involving multiple specialists and tests. GeneDx is working to streamline this process by moving genomic testing earlier into the diagnostic workflow. This approach can reduce the time and resources spent on sequential diagnostic procedures, ultimately leading to better patient outcomes.
Recognizing Leadership in Health Equity
The Fierce 50 recognition highlights the diverse contributions driving advancements in medicine and healthcare. Ayla Ellison, editor-in-chief of Fierce Life Sciences and Healthcare, noted that progress in the industry comes from various sources, including labs, executive leadership, community clinics, and advocacy work. The 2026 honorees represent the multifaceted nature of impact in healthcare, from biotech innovations to grassroots efforts.
Stueland’s selection in the Health Equity category underscores the potential of genomic diagnosis to improve access to answers for patients with difficult-to-identify conditions. GeneDx’s strategy centers on using its accumulated genomic and clinical data to support the interpretation of genetic variants, connecting findings with clinical evidence, and delivering actionable information within a timeframe that can influence medical decisions.
As the healthcare industry continues to evolve, the integration of genomic medicine into standard clinical practice is poised to revolutionize patient care. GeneDx, under the leadership of Katherine Stueland, is at the forefront of this transformation, driving the future of genomic precision medicine and improving health outcomes for patients worldwide.
